RARE CANCER RESEARCH FOUNDATION
Balance Sheet
Fiscal Year Start:
Jan 1
Assets in 2024 (Year End)
$3,059,554
Cash & Equivalents
83%
Other Assets
13%
Receivables (Non-Related)
3%
Related-Party Receivables
0%
Inventories
0%
Prepaid Expenses
0%
Investments
0%
Property, Plant, & Equipment (net)
0%
Liabilities in 2024 (Year End)
$743,703
Payables & Accruals
97%
Deferred Revenue
3%
Grants Payable
0%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Other Liabilities
0%
Assets
2023
2024
Change
Cash & Equivalents
$2,881,110
$2,553,244
-11%
Receivables (Non-Related)
$127,681
$99,768
-22%
Related-Party Receivables
-
-
-
Inventories
-
-
-
Prepaid Expenses
$25,099
-
-
Investments
-
-
-
Property, Plant, & Equipment (net)
-
-
-
Other Assets
-
$406,542
-
Total Assets
$3,033,890
$3,059,554
+1%
Liabilities
2023
2024
Change
Payables & Accruals
$112,964
$718,703
+536%
Grants Payable
-
-
-
Deferred Revenue
$829,169
$25,000
-97%
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
-
-
Other Liabilities
-
-
-
Total Liabilities
$942,133
$743,703
-21%
Net assets
2023
2024
Change
Restricted Net Assets
-
$350,006
-
Unrestricted Net Assets
$2,091,757
$1,965,845
-6%
Net assets
2023
2024
Change
Net assets
+$2,091,757
+$2,315,851
+11%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)